Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China
· Delayed Price · Currency is CNY 17.50
+0.12 (0.69%)
At close: Apr 28, 2025, 2:57 PM CST
Jiangsu CoWin Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 125.88 | 171.34 | 521.6 | 338.46 | 233.21 | Upgrade
|
| Revenue Growth (YoY) | -26.53% | -67.15% | 54.11% | 45.13% | 215.41% | Upgrade
|
| Cost of Revenue | 55.48 | 67.55 | 160.69 | 95.02 | 53.35 | Upgrade
|
| Gross Profit | 70.4 | 103.79 | 360.91 | 243.44 | 179.86 | Upgrade
|
| Selling, General & Admin | 131.25 | 132.93 | 99.81 | 71.43 | 38.19 | Upgrade
|
| Research & Development | 99.23 | 88.26 | 74.02 | 38.58 | 23.76 | Upgrade
|
| Other Operating Expenses | -4.09 | 1.15 | 1.21 | 1.04 | 0.71 | Upgrade
|
| Operating Expenses | 226.4 | 243.14 | 184.55 | 112.51 | 63.42 | Upgrade
|
| Operating Income | -156 | -139.35 | 176.36 | 130.93 | 116.44 | Upgrade
|
| Interest Expense | - | -1.7 | -1.93 | -1.92 | -0.12 | Upgrade
|
| Interest & Investment Income | 14.61 | 24.43 | 9.13 | 7.53 | 2.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.52 | 6.08 | -1.09 | -1.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -17.46 | -0.06 | -0.12 | -0.3 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -158.86 | -116.16 | 189.52 | 135.16 | 117.12 | Upgrade
|
| Impairment of Goodwill | - | -4.27 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.6 | 13.41 | 1.59 | 0.42 | 1.47 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.19 | 1.24 | -0.51 | 1.26 | - | Upgrade
|
| Asset Writedown | -9.64 | - | -0.06 | - | -0.03 | Upgrade
|
| Other Unusual Items | - | 12.8 | 4.86 | 7.69 | 7.89 | Upgrade
|
| Pretax Income | -164.7 | -92.98 | 195.4 | 144.53 | 126.44 | Upgrade
|
| Income Tax Expense | -3.33 | -9.24 | 24.82 | 18.68 | 18.28 | Upgrade
|
| Earnings From Continuing Operations | -161.38 | -83.74 | 170.57 | 125.85 | 108.16 | Upgrade
|
| Minority Interest in Earnings | 4.17 | -0.67 | -11.31 | - | - | Upgrade
|
| Net Income | -157.21 | -84.41 | 159.26 | 125.85 | 108.16 | Upgrade
|
| Net Income to Common | -157.21 | -84.41 | 159.26 | 125.85 | 108.16 | Upgrade
|
| Net Income Growth | - | - | 26.55% | 16.36% | 1105.55% | Upgrade
|
| Shares Outstanding (Basic) | 111 | 112 | 92 | 84 | 70 | Upgrade
|
| Shares Outstanding (Diluted) | 112 | 112 | 93 | 84 | 70 | Upgrade
|
| Shares Change (YoY) | -0.60% | 20.87% | 10.07% | 20.59% | 29.55% | Upgrade
|
| EPS (Basic) | -1.41 | -0.75 | 1.72 | 1.50 | 1.55 | Upgrade
|
| EPS (Diluted) | -1.41 | -0.75 | 1.72 | 1.49 | 1.54 | Upgrade
|
| EPS Growth | - | - | 14.97% | -3.24% | 827.95% | Upgrade
|
| Free Cash Flow | -161.67 | -170.94 | 6.99 | 20.11 | 95.44 | Upgrade
|
| Free Cash Flow Per Share | -1.45 | -1.52 | 0.07 | 0.24 | 1.36 | Upgrade
|
| Dividend Per Share | - | - | 0.433 | - | - | Upgrade
|
| Gross Margin | 55.93% | 60.58% | 69.19% | 71.92% | 77.12% | Upgrade
|
| Operating Margin | -123.93% | -81.33% | 33.81% | 38.69% | 49.93% | Upgrade
|
| Profit Margin | -124.89% | -49.26% | 30.53% | 37.18% | 46.38% | Upgrade
|
| Free Cash Flow Margin | -128.44% | -99.77% | 1.34% | 5.94% | 40.92% | Upgrade
|
| EBITDA | -127.33 | -116.09 | 189.71 | 138.85 | 121.03 | Upgrade
|
| EBITDA Margin | -101.16% | -67.75% | 36.37% | 41.02% | 51.90% | Upgrade
|
| D&A For EBITDA | 28.67 | 23.26 | 13.35 | 7.91 | 4.6 | Upgrade
|
| EBIT | -156 | -139.35 | 176.36 | 130.93 | 116.44 | Upgrade
|
| EBIT Margin | -123.93% | -81.33% | 33.81% | 38.69% | 49.93% | Upgrade
|
| Effective Tax Rate | - | - | 12.71% | 12.93% | 14.46% | Upgrade
|
| Revenue as Reported | - | 171.34 | 521.6 | 338.46 | - | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.